Discovery of α2‐plasmin inhibitor and its congenital deficiency

Aoki, Nobuo

doi:10.1111/j.1538-7836.2004.01055.x

Cited by 28 publications

(27 citation statements)

References 50 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 The constitutional PI deficiency is a rare disease. 3 To this day, we only know of forty cases. 1 Following a trauma or a surgery, and during the resorption of the clot, this deficiency leads to hemorrhages that can persist for several weeks.…”

Section: Discussioncontrasting

confidence: 58%

See 1 more Smart Citation

Plasmin inhibitor deficiency: A case report

Aissaoui¹,

Cherkab²,

Barrou³

2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 58%

“…In our case, the post-circumcision bleeding persisted for one month, and the hemothorax appeared one week after the accident, announcing a defect in fibrinolysis. This symptomatology can also evoke a constitutional deficit in factor XIII, 3 and however, the dosage of this factor was normal in our case.…”

Section: Discussionmentioning

confidence: 99%

Plasmin inhibitor deficiency: A case report

Aissaoui¹,

Cherkab²,

Barrou³

2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…In recent years, few studies have examined the important regulators of fibrinolysis [32]. Alpha-2-antiplasmin and its deficiency were identified in a report investigating the difficulty in maintaining haemostasis in patients who did not have impaired blood coagulation.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Fibrinolytic Inhibitors: Alpha-2-Antiplasmin and Plasminogen Activator Inhibitor 1 in Patients with Obstructive Sleep Apnoea

et al. 2016

View full text Add to dashboard Cite

Obstructive sleep apnoea (OSA) induces thrombophilia and reduces fibrinolysis. Alpha-2-antiplasmin (a-2-AP) and plasminogen activator inhibitor 1 (PAI-1) are major inhibitors of the fibrinolytic system. Increased concentrations of these factors are associated with a higher risk of cardiovascular diseases. The aim of this study was to assess plasma a-2-AP and PAI-1 in patients with OSA and evaluate correlations with the polysomnographic record and selected risk factors of cardiovascular diseases. The study group comprised 45 patients with OSA, and the control group consisted of 19 patients who did not meet the diagnostic criteria of OSA. Plasma a-2-AP and PAI-1 concentrations were assessed by enzyme-linked immunosorbent assay (ELISA). In the study group, the median value of plasma a-2-AP was higher than that of the control group (157.34 vs. 11.89 pg/ml, respectively, P<0.0001). A-2-AP concentration increased proportionally to the severity of OSA. The concentration of a-2-AP was positively correlated with the apnoea-hypopnoea index (AHI), apnoea index (AI), respiratory disturbances time (RDT), and desaturaion index (DI), and negatively correlated with mean and minimal oxygen saturation (SpO2 mean, SpO2 min, respectively). The median value of PAI-1 was higher in the study group than the control group (12.55 vs. 5.40 ng/ml, respectively, P = 0.006) and increased along with OSA severity. PAI-1 concentration was positively correlated with AHI, AI, RDT, DI, and body mass index (BMI) and negatively correlated with SpO2 mean and SpO2 min. Higher plasma concentrations of a-2-AP and PAI-1 in patients with OSA indicated that these patients had increased prothrombotic activity. OSA increases the risk of cardiovascular complications as it enhances prothrombotic activity.

show abstract

“…I read with great interest the historical sketch ‘Discovery of α 2 ‐plasmin inhibitor ( α 2 ‐PI) and its congenital deficiency’ by Professor Aoki [1]. Like Professor Aoki, I was working in the late 1960s and early 1970s on plasma inhibitors of plasmin and plasminogen activation.…”

mentioning

confidence: 99%

“…We now know as discussed by Professor Aoki [1] that the site in the plasminogen molecule which binds α 2 ‐PI is the same site by which plasminogen binds to fibrin, and that adsorption of plasminogen to fibrin is competitively inhibited by α 2 ‐PI. In the presence of chloride ions, α 2 ‐PI can effectively inhibit activator‐induced fibrinolysis whilst in the presence of acetate ions inhibition is reduced.…”

mentioning

confidence: 99%